MO stock forecast, quote, news & analysis

Key Takeaways

• Altria Group stock has declined approximately 2.1% over the last 30 days, trading near $71.59, reflecting modest consolidation after a strong year-to-date rally of roughly 28%.
• The company delivered a first-quarter earnings beat in April 2026, posting EPS of $1.32 on revenue of $4.76 billion, both above analyst consensus estimates.
• Altria declared a quarterly dividend of $1.06 per share, translating to an annualized yield of approximately 5.9%, reinforcing its status as an income-oriented holding.
• Sal Mancuso officially succeeded Billy Gifford as CEO in May 2026, marking a leadership transition at a pivotal moment in the company's smoke-free transformation.
• Analyst sentiment remains mixed with a consensus Hold rating; price targets range from $59 to $82, with UBS recently raising its target to $79.
• Upcoming Q2 2026 earnings, expected around July 30, will be a critical catalyst for assessing the trajectory of combustible volumes and smoke-free product momentum.

Current Market Snapshot

Altria Group (MO) shares closed at $71.59 on July 9, 2026, reflecting a modest pullback of roughly 2% over the trailing 30-day period. The stock has been trading within a consolidation range after reaching a 52-week high of $74.56 earlier this year. Despite recent softness, MO remains up substantially on a year-to-date basis, supported by strong first-quarter results and continued investor appetite for defensive, high-dividend-yielding equities. The broader Consumer Staples sector has outperformed the S&P 500 over the past month, though Altria has lagged slightly behind its sector peers during this window. Trading volumes have been relatively steady, and institutional ownership remains high at approximately 57% of outstanding shares, underscoring the stock's position as a core holding for many income-focused portfolios.

Altria Group (MO) Business Overview and Competitive Position

Altria Group is the largest tobacco company in the United States, with a portfolio spanning both combustible and smoke-free nicotine products. Its wholly owned subsidiaries include Philip Morris USA, the nation's most profitable cigarette manufacturer and home to the flagship Marlboro brand; John Middleton, a leading cigar maker; and U.S. Smokeless Tobacco Company, the global leader in moist smokeless tobacco. Altria has been actively expanding its smoke-free footprint through NJOY (e-vapor products with FDA marketing granted orders), Helix Innovations (the on! oral nicotine pouch brand), and the Horizon Innovations joint venture focused on heated tobacco sticks. The company also holds significant equity stakes in Anheuser-Busch InBev and Cronos Group. With a market capitalization of approximately $119 billion, a price-to-earnings ratio around 15, and a beta of 0.45, Altria is widely viewed as a defensive stalwart with strong cash flow generation and an entrenched competitive moat in the regulated U.S. nicotine market.

Recent Developments Driving MO

Several factors have shaped Altria's stock performance over the past month. The company's first-quarter 2026 earnings, released on April 30, surpassed expectations with adjusted EPS of $1.32 versus the $1.25 consensus on revenue of $4.76 billion, driven by resilient smokeable product income and improved pricing. Management reaffirmed full-year 2026 adjusted diluted EPS guidance of $5.56 to $5.72, representing 2.5% to 5.5% growth from the 2025 base. The annual shareholder meeting in May formalized the CEO transition from Billy Gifford to Sal Mancuso, a 30-year Altria veteran who previously served as CFO. The board also declared the regular quarterly dividend of $1.06 per share, maintaining Altria's long-standing track record of shareholder returns.

On the analyst front, UBS raised its price target to $79 in early July, citing confidence in accelerating EPS growth into 2027, while Stifel and Goldman Sachs maintained Buy ratings with $77 targets. On the more cautious side, Barclays reiterated an Underweight rating, and Jefferies maintained an Underperform stance, reflecting ongoing debate around combustible volume declines and regulatory risk. Notably, Moody's downgraded Altria's long-term senior unsecured credit rating to Baa2, highlighting reduced free cash flow tied to litigation-related collateral requirements. Additionally, Altria's U.S. Smokeless Tobacco subsidiary announced plans to close its Nashville manufacturing facility and consolidate operations in Kentucky by early 2028. FDA regulatory developments, including proposed rules for foreign tobacco manufacturer facility registration, remain a closely watched factor across the industry.

Trending AI Robots

For investors seeking data-driven trading strategies, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots active across thousands of tickers. Tickeron's platform hosts hundreds of algorithmic trading bots, each designed with distinct strategies, timeframes, and risk profiles. The Trending section highlights only those bots currently demonstrating the strongest performance metrics and market relevance, making it a useful resource for traders looking to complement their own analysis with AI-driven signals. Whether focused on short-term momentum, swing trading, or longer-term value plays, the bots span a wide range of approaches tailored to different market conditions. Explore the Trending AI Robots page to see which strategies are resonating in the current market environment.

2026 Outlook and What Investors Should Watch

Looking ahead, Altria's Q2 2026 earnings report, anticipated around July 30, will be a pivotal event. Analysts project EPS of approximately $1.50 on revenue near $5.35 billion. Key areas of focus will include Marlboro's market share stability, volume trends in the smokeable segment, and growth metrics for on! oral nicotine pouches and NJOY e-vapor products. The pace of the company's smoke-free transition under CEO Sal Mancuso's leadership will be scrutinized, particularly any updates on the potential reintroduction of NJOY ACE and new on! Plus pouch variants. Macroeconomic factors such as consumer spending resilience, regulatory actions from the FDA on nicotine product authorizations and enforcement, and the trajectory of cigarette import and export activity will also influence results. While the dividend remains well-covered with a payout ratio near 89%, investors will monitor free cash flow generation closely—especially given Moody's recent credit rating action and ongoing litigation-related financial obligations. Competitive pressures from PM and BTI in the smoke-free category add further complexity to the long-term growth narrative. For income-oriented investors, Altria's attractive yield and stable business model continue to offer a compelling proposition, though regulatory and volume headwinds remain persistent overhangs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations